Shots:

• Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further development & commercialization of a product
• BMS has exercised its option to license Evotec’s EVT8683 after 4.5yrs. of collaboration. Evotec’s iPSC platform allows screening of human iPSC-based disease models at high throughput in combination with unbiased transcriptome analysis
• EVT8683 is a small molecule targeting a key cellular stress response for multiple neurodegenerative indications and is ready to enter clinical development. The candidate was originated from Evotec’s iPSC discovery platform

Ref: Evotec | Image: BMS